Business Wire

Visa Launches Validator Node on Tempo Blockchain

14.4.2026 15:06:00 CEST | Business Wire | Press Release

Share

Visa (NYSE:V), a global leader in digital payments, today announced it has officially launched its validator node on the Tempo network, marking a key milestone in Visa’s continued advancement of blockchain infrastructure leadership and its role in shaping stablecoin payments. The launch underscores Visa’s commitment to running critical blockchain operations in-house and strengthening the foundations of onchain payment innovation.

Tempo, the next generation blockchain built for agentic commerce and real-time payments, has expanded its validator ecosystem to include leading financial and commerce partners. Visa, Stripe, and Zodia Custody by Standard Chartered will serve as the first external validators to join the Tempo network, with additional participants to be announced by Tempo.

“We’ve spent years building our expertise in blockchain, and now we’re expanding that work by running critical blockchain infrastructure ourselves,” said Cuy Sheffield, Head of Crypto, Visa. “By operating a validator on Tempo, we’re extending Visa’s commitment to reliability, security, and trust into blockchain networks – supporting the development of stablecoin payment systems that meet the high operating standards our clients and partners expect.”

Visa’s validator node has been configured and managed in-house, following six months of joint work with Tempo’s engineering team to directly integrate Visa’s secure infrastructure to the Tempo network. This approach places Visa at the core of transaction validation and supports the overall security of the network. By operating as an anchor validator during this initial phase, Visa is helping ensure Tempo operates with the reliability, resilience, and performance required for emerging payment use cases.

"Visa processes billions of transactions across nearly every country in the world. That kind of operational rigor is exactly what we look for in validators on Tempo, built for payments at enterprise scale,” said Nischay Upadhyayula, GTM, Tempo. “They've been a design partner since day one, and joining as a validator is a natural extension of that work."

The validator launch aligns with Visa’s ongoing roadmap for blockchain-driven payment innovation and reflects Visa’s commitment to shaping the future of stablecoin payments by working alongside partners to enhance resilience, interoperability, and security across the ecosystem.

Frequently Asked Questions (FAQ)

Q: What is Tempo?

Tempo is a purpose-built Layer-1 blockchain and is designed for agentic commerce and machine-to-machine payments.

Q: What is a validator node?

A validator node is a computer system that participates in a blockchain network by confirming and ordering transactions into blocks, helping secure the network through maintaining consensus on the ledger’s state.

Q: Why is Visa running a validator node?

Running a validator node allows Visa to apply its deep technical expertise directly within the Tempo network, helping support secure, reliable, and scalable onchain payments that are designed to meet client and regulatory expectations.

Q: Does Visa earn anything for its role?

Validators on Tempo are rewarded in stablecoins when serving as “lead validators” who package transactions into blocks to be added to the blockchain.

Q: Is Visa a validator on any other blockchains?

Yes. Visa has also been selected as the first major global payments company to serve as a Super Validator on the Canton Network, where it will help banks and financial institutions explore privacy‑preserving onchain payment flows.

Q: How can organizations engage with Visa on crypto or stablecoins strategy?

Visa Consulting & Analytics (VCA) offers a Stablecoins Advisory Practice that helps clients define stablecoin strategies and build onchain capabilities aligned with their business goals. To connect with an advisor, email VCA@visa.com.

About Visa

Visa (NYSE: V) is a world leader in digital payments, facilitating transactions between consumers, sellers, financial institutions and government entities across more than 200 countries and territories. Our mission is to connect the world through the most innovative, convenient, reliable and secure payments network, enabling individuals, businesses and economies to thrive. We believe that economies that include everyone everywhere, uplift everyone everywhere and see access as foundational to the future of money movement. Learn more at Visa.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260414794567/en/

Contacts

Media Contacts
Jackie Dresch - jdresch@visa.com
Conor Febos – cfebos@visa.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press Release

Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press Release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press Release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye